Cissus for Joint and Tendon Pain

In bodybuilding and strength-sport circles Cissus quadrangularis has a specific reputation: the thing you take when your elbows hurt, your knees ache under heavy squats, or a tendon is grumbling. It is sold as a joint, tendon and ligament repair agent, often beside creatine and collagen, and the claim is repeated with a confidence you would expect from a well-trialled drug.

The human evidence for that claim is one small pilot study. That is not a rhetorical flourish; it is the count. Everything else supporting the joint and tendon market is either extrapolated from the plant's bone-healing tradition, or drawn from cell-culture and rodent anti-inflammatory work of the kind that exists for hundreds of plants. This page separates the three layers, names which claim rests on which, and points at the botanicals that have actually been asked the joint question properly.

Table of Contents

1. What the Fitness Market Actually Sells
2. The One Human Trial
3. Borrowed Evidence: Bone Is Not Cartilage
4. In Vitro Anti-Inflammatory Is Not Analgesic
5. Tendon and Ligament: The Weakest Claim
6. The Stack Problem
7. How Joint and Tendon Outcomes Are Actually Measured
8. Botanicals With More Human Data
9. Evidence Tiers, Ranked Honestly
10. What This Page Will Not Assert
11. Key Research Papers
12. Connections

What the Fitness Market Actually Sells

Strip the copywriting and the joint claims made for Cissus fall into four buckets, each requiring different proof.

1. Pain relief in joints stressed by training. An analgesic claim. Measurable, and the subject of the one trial that exists.
2. Repair of tendon and ligament tissue. A structural claim, and a much bigger one — it asserts that collagen turnover in a specific tissue changes. Nothing in the human literature tests this.
3. Protection or regeneration of cartilage. A disease-modifying claim of the type that has defeated pharmaceutical programmes with far larger budgets. No human data.
4. Faster return to training after injury. A functional claim, which would need a defined injury, a randomised design and a return-to-play endpoint. Never studied.

Only bucket 1 has a human study behind it, and that study was not designed to prove anything. The other three are inference from the plant's fracture-healing reputation — and the inference is weaker than it sounds, for reasons that come next.

The One Human Trial

Evidence tier: single small pilot, self-reported outcome, not powered for efficacy.

The anchor citation is a pilot study by Bloomer and colleagues, published in The Physician and Sportsmedicine in 2013, reporting reduced joint pain versus placebo over eight weeks in exercise-trained men taking a Cissus extract. It is genuinely a randomised placebo-controlled study, and it should be credited as one. It also has to be read for what it is:

• A pilot study is designed to find out whether a full trial is worth running. The authors framed it that way. It was not powered to establish efficacy, and a positive pilot is a signal to test further, not a result to sell against.
• The outcome was self-reported joint pain in men who exercise — a subjective endpoint in a population with fluctuating training loads, and one that responds strongly to placebo.
• The population was narrow. Exercise-trained men with training-related joint discomfort are not people with osteoarthritis, rheumatoid arthritis or a diagnosed tendinopathy. The result does not transfer to those conditions.
• The confirmatory trial has never appeared. Over a decade later, the larger study the pilot was meant to justify has not been published. That silence is itself information: a positive pilot on a commercially valuable supplement that nobody follows up is a pattern worth noticing.

The Sawangjit systematic review and meta-analysis in Phytotherapy Research (2017) pooled the randomised evidence on Cissus quadrangularis across indications and concluded that the quantity and quality of trials limit what can be said. Nothing published since changes that for joints.

Borrowed Evidence: Bone Is Not Cartilage

The commonest way a herb page overstates itself is by importing evidence from a neighbouring claim and not labelling the import. Cissus joint marketing does this in three distinct ways, and each needs flagging where it occurs rather than once in a preamble.

Tissue substitution

The plant's real evidence base — such as it is — concerns fracture repair: osteoblasts, mineralisation, callus formation. Cartilage is made by chondrocytes, is avascular, and does not heal by the callus mechanism at all. Tendon is dense, poorly vascularised type-I collagen with notoriously slow turnover. An osteogenic result does not imply a chondroprotective or tendon-healing one, and in some respects points the other way: agents that drive mineralisation are not what you want in cartilage. Whenever you see bone-healing citations offered for a joint product, that is tissue substitution.

Route and preparation substitution

Traditional use for sprains and joint pain was frequently topical — crushed fresh stem applied as a paste. A capsule of concentrated dried-stem extract is a different route and a different preparation, and a topical tradition supports an oral capsule only by assumption. The cell-culture bone work most often cited uses a petroleum-ether extract, which pulls the lipophilic sterol fraction and is not what a water or ethanol product delivers.

Family substitution

Because Cissus is in the grape family and contains resveratrol-family stilbenes, marketing sometimes reaches for the resveratrol or grape-polyphenol literature on joint inflammation. That is a different plant, a different compound concentration and a different intervention. See Resveratrol for what that literature actually says on its own terms — and do not credit it to this vine.

In Vitro Anti-Inflammatory Is Not Analgesic

Cissus extracts inhibit inflammatory mediators in cultured cells and reduce swelling in standard rodent tests such as carrageenan paw oedema. Published work also reports inhibition of cyclooxygenase and lipoxygenase pathways by stem extracts in vitro. All of this is real laboratory data, and none of it establishes that a capsule relieves a person's knee pain. Three gaps sit between them.

1. Concentration. An in-vitro inhibitory concentration says nothing about what appears in human plasma after an oral dose, still less what reaches synovial fluid. Without human pharmacokinetics — which do not exist for this plant's constituents — the assay cannot be scaled to a dose.
2. Endpoint. Reduced paw swelling in a rodent is an anti-oedema effect. Human joint pain is a perception with inflammatory, mechanical and central components, which is why analgesic trials use validated pain scales and not calipers.
3. Non-specificity. Nearly every plant extract inhibits something in an inflammation assay. A finding shared with hundreds of botanicals cannot support a claim specific to joints.

The honest statement is that Cissus has plausible anti-inflammatory pharmacology and one small positive analgesic pilot. Reporting the first as though it demonstrated the second is the single most common error in supplement writing about this plant.

Tendon and Ligament: The Weakest Claim

The tendon and ligament claims deserve separating out because they are the ones most confidently made and least supported.

There is no human trial of Cissus in tendinopathy, ligament injury, or post-operative ligament reconstruction. Not a negative trial — an absent one. That distinction matters: the claim has never been tested, so it is unknown rather than refuted. But absence here is not an excuse, because tendinopathy is a well-studied condition with validated outcome measures and a mature trial literature on loading protocols. The tools exist. They have not been pointed at this plant.

The mechanism story usually offered is that Cissus supports collagen synthesis. Two things are true and pull apart:

• The fresh stem is a good source of vitamin C, which is genuinely required for the prolyl and lysyl hydroxylation steps in collagen cross-linking. That is real biochemistry — see Vitamin C, Proline and Lysine.
• The concentrated extract in a capsule carries essentially none of that vitamin C. So the mechanism most plausibly connecting this plant to tendon repair belongs to the vegetable, not the product. Anyone reasoning from one to the other has switched interventions midway.

If the goal is tendon collagen, the interventions with actual human data are progressive loading protocols, adequate protein intake, vitamin C sufficiency, and — with modest but real trial support — collagen peptides taken around training. See Collagen, Achilles Tendinopathy and Tendinitis.

The Stack Problem

Cissus reaches most of its users inside a stack, and this shapes everything about attribution.

Joint products routinely combine it with glucosamine, chondroitin, MSM, collagen, boswellia, turmeric and black pepper extract. Fat-loss products combine it with caffeine and green tea. A lifter taking a joint stack alongside a pre-workout may be consuming eight actives at once. Three consequences:

1. Perceived benefit cannot be attributed. If the elbow feels better, boswellia and turmeric both have more human trial data than Cissus and are the more likely candidates. Improvement on a stack is weak evidence for any single ingredient in it.
2. Adverse effects cannot be attributed either. Headache, jitteriness or gut upset on a stack containing caffeine is not a Cissus side effect, though it is often recorded as one.
3. Interaction assessment becomes guesswork. Reported blood-glucose effects, discussed in Dose, Formulations and Safety, matter more when a product also contains chromium or berberine-like actives — and nobody has studied those combinations.

Practical consequence: if you want to know whether Cissus does anything for your joints, the only informative test is a single-ingredient product taken while nothing else changes. That is also, not coincidentally, the version nobody sells you.

How Joint and Tendon Outcomes Are Actually Measured

The most useful thing a page can do with an untested claim is specify how the outcome would be measured — which disposes of the argument that traditional remedies cannot be trialled. Every instrument below is validated and in routine use.

• WOMAC and KOOS — the standard patient-reported instruments for knee osteoarthritis pain, stiffness and function.
• VAS or NRS pain scores, with a defined minimal clinically important difference, so a statistically significant change can be judged for whether a patient would notice it.
• VISA-A (Achilles) and VISA-P (patellar) — tendinopathy-specific severity scores.
• Ultrasound and MRI for tendon thickness, hypoechoic change and neovascularisation — structural endpoints, not just symptoms.
• Joint space width on radiograph, the regulatory endpoint for a genuine disease-modifying osteoarthritis claim.
• Isokinetic strength and return-to-sport time, the functional endpoints an athlete actually cares about.
• Inflammatory markers such as high-sensitivity CRP, as a mechanistic co-endpoint — see hs-CRP.

None of these has been applied to Cissus quadrangularis in a trial designed to answer the joint or tendon question. That is the finding.

Botanicals With More Human Data

Naming the better-tested alternatives is more useful than a warning, and it pre-empts the objection that nobody trials plants.

• Boswellia serrata — multiple randomised placebo-controlled trials in knee osteoarthritis, including work by Kimmatkar and colleagues in Phytomedicine (2003) and later trials of standardised AKBA-enriched extracts. Not definitive, but a different order of evidence.
• Turmeric and curcumin — the largest botanical trial literature in arthritis, pooled in systematic reviews such as that of Daily and colleagues in the Journal of Medicinal Food (2016). Bioavailability remains the central problem.
• Devil's claw (Harpagophytum) — reviewed in the herbal low-back-pain literature with moderate support.
• Willow bark — salicin-containing, with trial data in back and joint pain and a coherent mechanism.
• Ginger — several knee-osteoarthritis trials, modest effects.
• Collagen peptides — including a 24-week study by Clark and colleagues in Current Medical Research and Opinion (2008) in athletes with activity-related joint pain, which is the closest thing to the population Cissus is marketed to.

This is not a claim that these work and Cissus does not. It is a statement about how many times each has been asked the question.

Evidence Tiers, Ranked Honestly

Ranked against the strength of the evidence rather than the volume of the marketing — which reverses the usual order.

1. Training-related joint discomfort in men. Tier: preliminary human. One randomised pilot, self-reported outcome, unreplicated. The weakest form of positive human evidence, but genuinely positive.
2. Anti-inflammatory pharmacology. Tier: in vitro and rodent. Real, non-specific, and not translatable to an analgesic dose without human pharmacokinetics.
3. Osteoarthritis symptom relief. Tier: absent. Never trialled in a diagnosed OA population.
4. Tendinopathy and ligament repair. Tier: absent. No trial of any design.
5. Cartilage protection or regeneration. Tier: absent, and mechanistically the least plausible — the bone-facing pharmacology most often cited does not point at cartilage.
6. What is best established about Cissus in this domain is a limitation: the confirmatory trial that a positive 2013 pilot called for has not been run in more than a decade.

What This Page Will Not Assert

Some figures and statements circulate confidently and cannot be sourced. Naming the refusal is more honest than picking a plausible number.

• A joint-pain dose. No dose-finding study exists for any joint indication. Product labels carry numbers chosen commercially, not clinically.
• A percentage pain reduction. Repeating a single pilot's effect size as though it were an expected result would misrepresent what a pilot is.
• A "cortisol-blocking" mechanism. Widely asserted in the fitness market; no adequate human data shows a cortisol effect, and none links such an effect to joint pain.
• A ketosterone content or its pharmacology. The assay is not standardised between laboratories and the anabolic mechanism attributed to the fraction is a hypothesis with a trade name.
• An interaction list for stacks. Cissus combined with caffeine, glucosamine, turmeric or chromium has not been studied. Saying "no known interactions" here would be misleading — it means no interaction study exists, which is absent data, not reassurance.

Key Research Papers

Every citation is a PubMed search built from author names and distinctive title words rather than a numeric identifier, so a link cannot silently resolve to the wrong paper. Confirm the record before relying on it. Where a paper is about a different plant or a different tissue, that is labelled at the citation.

1. The one joint trial. Bloomer RJ, Farney TM, McCarthy CG, Lee SR. Cissus quadrangularis reduces joint pain in exercise-trained men: a pilot study. The Physician and Sportsmedicine, 2013. Read the sample size and the authors' own framing. Find on PubMed.
2. Quality appraisal of the whole Cissus literature. Sawangjit R, Puttarak P, Saokaew S, Chaiyakunapruk N. Efficacy and safety of Cissus quadrangularis L. in clinical use: a systematic review and meta-analysis of randomised controlled trials. Phytotherapy Research, 2017. Find on PubMed.
3. Industry-adjacent review. Stohs SJ, Ray SD. A review and evaluation of the efficacy and safety of Cissus quadrangularis extracts. Phytotherapy Research, 2013. Read the competing-interests statement. Find on PubMed.
4. Anti-inflammatory pharmacology — in vitro and rodent, not clinical. Published work on Cissus quadrangularis extracts and inflammatory mediators, including cyclooxygenase and lipoxygenase pathway inhibition. Confirm journal and year from the records; treat as mechanism, not analgesia. Search PubMed.
5. Analgesic and anti-oedema rodent tests. Reports of analgesic and anti-inflammatory activity of Cissus quadrangularis in standard rodent models. Anti-oedema and writhing endpoints — not human pain scales. Search PubMed.
6. The bone work that gets borrowed for joints. Potu BK and colleagues. Petroleum ether extract of Cissus quadrangularis enhances bone marrow mesenchymal stem cell proliferation and facilitates osteoblastogenesis. Clinics, 2009. Different tissue and a lipophilic solvent — osteoblasts, not chondrocytes or tenocytes. Find on PubMed.
7. Comparator — different plant. Kimmatkar N and colleagues. Efficacy and tolerability of Boswellia serrata extract in treatment of osteoarthritis of knee: a randomised double-blind placebo-controlled trial. Phytomedicine, 2003. Cited to show what a joint trial looks like, not as evidence for Cissus. Find on PubMed.
8. Comparator — different plant. Daily JW, Yang M, Park S. Efficacy of turmeric extracts and curcumin for alleviating the symptoms of joint arthritis: a systematic review and meta-analysis of randomised clinical trials. Journal of Medicinal Food, 2016. Find on PubMed.
9. Comparator — different intervention. Clark KL and colleagues. 24-week study on the use of collagen hydrolysate as a dietary supplement in athletes with activity-related joint pain. Current Medical Research and Opinion, 2008. The closest published trial to the population Cissus is marketed at. Find on PubMed.
10. How tendon outcomes are measured. The VISA-A score for Achilles tendinopathy — a validated instrument that has never been used to test this plant. Search PubMed.
11. How joint outcomes are measured. WOMAC and KOOS in knee osteoarthritis trials, with minimal clinically important difference thresholds. Search PubMed.

Live PubMed Searches

1. Cissus quadrangularis and joint pain
2. Cissus quadrangularis and tendon — note how little returns.
3. Cissus quadrangularis and cartilage
4. Cissus quadrangularis and cortisol — the fitness market's favourite mechanism.
5. Loading protocols for tendinopathy — what does have evidence

External Resources

• NCCIH — how botanical evidence is graded.
• NIAMS — the US institute for arthritis and musculoskeletal disease.
• PubMed — the primary literature.

Connections

• All Herbs
• Cissus quadrangularis — botany, names, constituents, full cautions.
• Cissus for Bone and Fracture Healing — the real evidence base, and why it does not transfer to cartilage.
• Cissus for Weight and Metabolic Outcomes — the other fitness-market claim, and its trials.
• Cissus: Dose, Formulations and Safety — stacks, glucose effects, and what a dose means here.
• Boswellia — multiple randomised knee-osteoarthritis trials.
• Turmeric — the largest botanical arthritis literature.
• Devil's Claw — moderate support in low back and joint pain.
• Willow Bark — salicin, and a mechanism that is not in dispute.
• Ginger — modest but real knee-osteoarthritis trial data.
• Osteoarthritis — the condition Cissus has never been trialled in.
• Achilles Tendinopathy — validated outcome scores, and loading protocols that work.
• Tendinitis — what tendon pain actually responds to.
• Rotator Cuff Tear — the lifter's injury the marketing implies it treats.
• Collagen — the peptide trials in athletes with joint pain.
• Vitamin C — the collagen cofactor the fresh stem supplies and the capsule does not.
• Proline — with lysine, the residue whose hydroxylation needs vitamin C.
• Resveratrol — the grape-family literature that keeps getting borrowed for this vine.
• hs-CRP — the inflammatory marker a real trial would track.

Back to Table of Contents